

RECEIVED

JUN 10 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Bernd Riedl et al.

Serial No.: 10/042,226

Group Art Unit: 1614

Filed: January 11, 2002

Examiner: James Reamer

For: ω -CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. ____; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an International Search Report dated ____; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed ____.

ADDITIONAL INFORMATION

[NONE?]

LANGUAGE

- ☒ All listed materials are in the English language; see 37 C.F.R. § 1.98.
- ☐ Non-English language references:
 - ☐ The reference(s): _____ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): _____, respectively.
 - ☐ (An) English-language translation(s) of the references: _____ is (are) provided.
 - ☐ A commercial English-language abstract of reference(s) _____ is (are) provided.

- ☐ An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

FEES

- ☒ No fee is required for this Information Disclosure Statement because:
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
- ☒ This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
- ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
- ☐ This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- ☐ A fee is required for this Information Disclosure Statement:
- ☐ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in § 1.17(p).
- ☐ This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.


CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Richard J. Traverso (Reg. No. 30,595)
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 24A

Date: June 7, 2002

RJT:lvb
K:\Bayer\24A\ids 6-7-02.doc

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DKT. NO. BAYER 24A	SERIAL NO. 10/042,226
	APPLICANT Bernd Riedl et al.	
	FILING DATE January 11 2002	GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
	AA	502,504	8/1/1893	Thoms		
	AB	1,742,156	2/31	Fritzky		
	AC	2,046,375	7/36	Goldstein et al.		
	AD	2,093,265	9/36	Coffby et al.		
	AE	2,288,422	6/42	Rohm		
	AF	2,649,476	8/18/53	Martin		
	AG	2,683,082	7/54	Hill et al.		
	AH	2,722,544	11/1/55	Martin		
	AI	2,745,874	5/56	Schetty et al.		
	AJ	2,781,330	2/57	Downey		
	AK	2,797,214	6/25/57	Werner Bossard		
	AL	2,867,659	1/59	Model et al.		
	AM	2,877,268	3/59	Applegate et al.		
	AN	2,960,488	11/60	Tamblyn et al.		
	AO	2,973,386	2/61	Weldon		
	AP	3,151,023	9/64	Martin		
	AQ	3,200,035	8/65	Martin et al.		
	AR	3,230,141	1/66	Frick et al.		
	AS	3,424,760	01/28/69	Helsley et al.		
	AT	3,424,761	01/28/69	Helsley et al.		
	AU	3,424,762	01/28/69	Helsley et al.		
	AV	3,547,940	12/15/70	Brantley		
	AW	3,646,059	02/29/72	Brantley		
	AX	3,689,550	9/72	Schellenbaum et al.		
	AY	3,743,498	7/3/73	Brantley		
	AZ	3,754,887	08/28/73	Brantley		
	BA	3,823,161	07/09/74	Lesser		
	BB	3,828,001	8/74	Broad et al.		
	BC	3,860,645	1/95	Nikawitz		
	BD	3,990,879	11/9/1976	Soper		
	BE	4,001,256	1/4/97	Callahan et al.		
	BF	4,009,847	3/1/77	Aldrich et al.		
	BG	4,042,372	8/16/1977	Harper		
	BH	4,062,861	12/13/77	Yukinaga et al.		
	BI	4,071,524	01/31/78	Banitt		
	BJ	4,111,680	09/05/78	Yukinaga et al.		

RECEIVED

JUN 10 2002

TECH CENTER 1600/2900

	BK	4,111,683	09/05/78	Singer			
	BL	4,116,671	09/26/78	Yukinaga et al.			
	BM	4,173,637	11/79	Nishiyama et al.			
	BN	4,173,638	11/79	Nishiyama et al.			
	BO	4,183,854	1/80	Crossley			
	BP	4,212,981	07/15/80	Yukinaga et al.			
	BQ	4,240,820	12/23/80	Dickore et al.			
	BR	4,405,644	9/20/83	Kabbe et al.			
	BS	4,410,697	10/18/83	Török et al.			
	BT	4,437,878	03/20/84	Acker et al.			
	BU	4,468,380	8/28/84	O'Doherty et al.			
	BV	4,473,579	9/25/84	Devries et al.			
	BW	4,511,571	4/85	Böger et al.			
	BX	4,514,571	04/30/85	Nakai et al.			
	BY	4,526,997	7/2/85	O'Doherty et al.			
	BZ	4,623,662	11/18/86	De Vries			
	CA	4,643,849	02/17/87	Hirai et al.			
	CB	4,740,520	4/88	Hallenbach et al.			
	CC	4,760,063	7/26/88	Hallenbach et al.			
	CD	4,808,588	02/28/89	King			
	CE	4,820,871	4/89	Kissener et al.			
	CF	4,863,924	9/89	Haga et al.			
	CG	4,983,605	1/91	Kondo et al.			
	CH	4,985,449	1/15/91	Haga et al.			
	CI	5,036,072	7/91	Nakajama et al.			
	CJ	5,059,614	10/22/91	Lepage et al.			
	CK	5,098,907	3/92	Kondo et al.			
	CL	5,130,331	07/14/92	Pascual			
	CM	5,162,360	11/10/92	Creswell et al.			
	CN	5,185,358	2/9/1993	Creswell			
	CO	5,312,820	5/17/94	Ashton et al.			
	CP	5,319,099	6/7/94	Kamata et al.			
	CQ	5,399,566	3/21/95	Katano et al.			
	CR	5,423,905	6/95	Fringeli			
	CS	5,429,918	7/4/1995	Seto et al.			
	CT	5,432,468	7/11/95	Moriyama et al.			
	CU	5,470,882	11/95	Dixon et al.			
	CV	5,500,424	3/19/96	Nagamine et al.			
	CW	5,508,288	04/16/96	Forbes et al.			
	CX	5,597,719	1/28/97	Freed et al.			
	CY	5,696,138	12/9/97	Olesen et al.			
	CZ	5,698,581	12/16/97	Kleemann et al.			
	DA	5,773,459	06/30/98	Tang et al.			
	DB	5,780,483	7/14/98	Widdowson et al.			
	DC	5,780,483	7/14/98	Widdowson et al.			
	DD	5,807,891	9/15/98	Bold et al.			

	DE	5,814,646	9/29/1998	Heinz			
	DF	5,886,044	3/23/99	Widdowson et al.			
	DG	5,891,895	4/6/99	Shiraishi et al.			
	DH	5,908,865	6/1/1999	Doi et al.			
	DI	5,965,573	10/12/99	Petrie et al.			
	DJ	6,004,965	12/21/99	Breu et al.			
	DK	6,005,008	12/21/99	Widdowson et al.			
	DL	6,020,345	2/1/00	Vacher et al.			
	DM	6,040,339	3/21/00	Yoshida et al.			
	DN	6,080,763	6/27/2000	Regan et al.			
	DO	6,093,742	7/25/00	Salituro et al.			
	DP	6,133,319	10/17/00	Widdowson			
	DQ	6,150,415	11/21/00	Hammock et al.			
	DR	6,174,901B1	1/16/01	Mantlo et al.			
	DS	6,178,399B1	1/23/01	Takebayashi et al.			
	DT	6,180,675B1	1/30/01	Widdowson et al.			
	DU	6,187,799B1	2/13/01	Wood et al.			
	DV	6,211,373B1	4/3/01	Widdowson et al.			
	DW	6,218,539B1	4/17/01	Widdowson et al.			
	DX	6,242,601B1	6/5/01	Breu et al.			
	DY	6,262,113B1	7/17/01	Widdowson et al.			
	DZ	6,271,261B1	8/7/01	Widdowson			
	EA	6,333,341B1	12/25/01	Mantlo et al.			
	EB	6,339,045B1	1/15/02	Kanno et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EC	90/02112	3/8/90	WO			
+	ED	93/18028	09/16/93	WO			
+	EE	93/24458	12/9/93	WO			
+	EF	94/14801	07/07/94	WO			
+	EG	94/22807	10/13/94	WO			
+	EH	94/18170	08/18/94	WO			
	EI	94/25012	11/10/94	WO			
+	EJ	95/02591	01/26/95	WO			
+	EK	95/07922	03/23/95	WO			
+	EL	95/13067	05/18/95	WO			
+	EM	95/31451	11/23/95	WO			
+	EN	95/33458	12/14/95	WO			
+	EO	96/10559	4/11/96	WO			
+	EP	96/25157 A1	8/22/96	WO			
+	EQ	96/40673	12/19/96	WO			
	ER	96/40675 A1	12/19/96	WO			
	ES	97/17329	5/15/97	WO			

RECEIVED

JUN 10 2002

TECH CENTER 1600/2900

ET	97/29743	8/21/97	WO				
EU	97/30992	8/28/97	WO				
EV	97/40028 A1	10/30/97	WO				
EW	97/49400	12/31/97	WO				
EX	97/49399	12/31/97	WO				
EY	97/45400	12/4/97	WO				
EZ	98/17267	4/30/98	WO				
FA	98/22103	5/28/1998	WO				
FB	98/22432	5/28/98	WO				
FC	98/52558	11/26/98	WO				
FD	98/52559	11/26/98	WO				
FE	99/00357	1/7/99	WO				
FF	99/00370	1/7/99	WO				
FG	99/23091	5/14/99	WO				
FH	99/24398	5/20/99	WO				
FI	99/32106	7/1999	WO				
FJ	99/32110	7/1/99	WO				
FK	99/32111	7/1/1999	WO				
FL	99/32436	7/1/99	WO				
FM	99/32437	7/1/99	WO				
FN	99/32455	7/1/1999	WO				
FO	99/32463	7/1/99	WO				
FP	99/33458	7/8/99	WO				
FQ	99/40673	8/12/99	WO				
FR	00/17175	3/30/2000	WO				
FS	00/43366A1	01/20/2000	WO				
FT	00/43384	7/27/2000	WO				
FU	00/55139	9/21/2000	WO				
FV	00/55152	9/21/2000	WO				
FW	0016371A1	3/5/80	EP				
FX	0 405 233	1/91	EP				
FY	0116932	8/29/84	EP				
FZ	242666	10/28/87	EP				
GA	335156	03/11/89	EP				
GB	371876	11/28/89	EP				
GC	425443A1	2/5/91	EP				
GD	459887	05/28/91	EP				
GE	676395	7/17/1996	EP				
GF	0202538A1	11/26/86	EP				
CG	860433A1	8/26/98	EP				
GH	0 523 437	5/31	Germany				
GI	0 511 468	10/30	Germany				
GJ	0 487 014	12/29	Germany				
GK	0 253 997	2/88	East Germany				
GL	2436179A1	2/6/1975	DE				

	GM	2436179C2	2/6/75	DE				
	GN	25 01 648	7/24/75	DE				
	GO	35 40 377 A1	11/14/85	DE				
	GP	35 29 247 A1	8/20/85	DE				
	GQ	3305866A1	02/19/83	DE				
	GR	3 532 47	3/91	Japan				
	GS	8 031841	11/19/96	Japan				
	GT	44 2569	2/69	Japan				
	GU	10-306078	11/17/98	Japan				
	GV	50-149668	11/75	Japan				
	GW	50-76072	6/75	Japan				
	GX	50-77375	6/75	Japan				
	GY	51 063170	1/6/76	Japan				
	GZ	51-80862	7/76	Japan				
	HA	53 086033	7/29/78	Japan				
	HB	55 98152	7/80	Japan				
	HD	55-124763	9/80	Japan				
	HE	55-162772	12/80	Japan				
	HF	0 771 333	3/57	Great Britain				
	HG	0 828 231	10/56	Great Britain				
	HH	0 921 682	3/63	Great Britain				
	HI	1,590,870	06/10/81	Great Britain				
	HJ	1 457 172	9/66	France				
	HK	2,146,707	10/12/95	Canada				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	HL	Caplus 86:72448, Abstract JP 57053785, Pyridine derivatives, Maeda Ryozyo et al., November 15, 1982
	HM	Caplus 84:180049, Abstract JP 56029871, Hamada Yoshinori et al., July 10, 1981
	HN	Caplus 84:43857, Abstract JP 58021626, Maeda Ryozyo et al., May 2, 1983
	HO	Caplus 95:61995, Abstract JP 55162772, Substituted acetic derivatives, Shionogi & Co., May 23, 1980
	HP	Abstract of EP 202,538
	HQ	Abstract of DE 3305866 (EP equivalent 116,932)
	HR	Abstract of EP 116,932
	HS	Abstract of EP 16,371
	HT	Abstract of EP 4931A equivalent 4,240,820)
	HU	Abstract of EP 676,395 (U.S. equivalent 5,698,581)
	HV	Abstract WO 9822103, Hedge 28 May 1998
	HW	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742
	HX	Tarzia, G. et al., "Whythesis and anit-inflammatory properties of some pyrrolo(1H,3H)[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.
	HY	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.

	HZ	Audia, James E., et al., "Potent, Selective Tetraphdro- β -carboline Antagonists of the Serotonin $2B$ ($5HT_{2B}$) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
	IA	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity $5-HT_{2B}$ Receptor Antagonist," March 17, 1995, pages 855-57.
	IB	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. ¹ A Generalised Monocyclic Rearrangement," 1967, 2005-07.
	IC	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
	ID	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
	IE	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
	IF	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
	IG	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
	IH	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
	II	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhiibitors," N.Y. Academy of Science, 1993, pages 149-70.
	IJ	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
	IK	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
	IL	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
	IM	G. Daum, et al., The ins and outs of Raf Kinases,," TIBS 19, November 1994, pages 474-80.
	IN	Grant, A.M. et al.: "Hypotensive thiadiazoles" J. Med. Chem. (1972), 15(10), 1082-4.
	IO	Russo, F. et al. "Synthesis of 2,6-substituted derivatives of 5H-1,3,4-thiadiazolo'3,2-a'-s triazine-5,7-dione" FARMACO, ED.SCI. (1978), 33(12), 972-83
	IP	Joseph T. Bruder and Imre Kovessi, "Adenovirus Infection Stimulates the Raf/MAPK Signaling Pathway and Induces Interleukin-8 Expression, May 17, 1996, pp. 198-404.
	IQ	Foussard-Blanpin, Odette: "Comparative pharmacodynamic study of variously substituted carboxamides of the central nervous ststem" Ann. Pharm. Fr. (1982), 40 (4), 339-50
	IR	Kubo, Hiroshi et al. "Herbicidal activity of 1,3,4-thiadiazole derivatives" J. Agr. Food Chem. (1970) , 18(1), 60-5
	IS	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
	IT	
	IU	
	IV	
	IW	
	IX	
	IY	
	IZ	
Examiner		Date Considered
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		